Overall, 39 of 157 (24.8%) intervention-group clinicians increased their use of GLP-1 RAs with their patients with T2D compared with 20 of 157 (12.7%) comparison-group clinicians. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.